MedPath

Acute Respiratory Infection Consortium

Active, not recruiting
Conditions
Influenza
Registration Number
NCT01021098
Lead Sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Brief Summary

Recently, the emergence and rapid global dissemination of novel swine-origin influenza A virus (H1N1) with unique epidemiologic characteristics has heightened awareness and concern of this viral pathogen, and its potential for major disruption of both civil and military stability. Although advances in medical and scientific technologies have improved our basic understanding of respiratory disease, many questions about the epidemiology and immunology of ARI remain unanswered. This study plans to initiate a multi-site, multi-disciplinary research collaboration, termed the Acute Respiratory Infection Consortium (ARIC) for the purpose of studying the etiology, epidemiology and immunology of influenza-like illness (ILI) in order to describe the natural history and risk factors for disease, as well as the characteristics of the host immune response.

At the core of the ARIC is the proposed observational, longitudinal study of the Natural History Study of ILI among active duty military members, healthy retirees, and their dependents recruited from both inpatient and outpatient settings of military treatment facilities (MTF) in the continental US to be followed for a total of four (4) visits over a 28-day period. Additionally, the investigators also propose to conduct a household-based study of influenza (Family Transmission Study) in which individuals who have a laboratory-confirmed influenza illness will be recruited and enrolled along with their family members for the purpose of studying transmission of influenza within households. Taken together, these studies will establish a longitudinal cohort of ILI among active duty members and their families, as well as a repository of biological specimens relevant to the epidemiology and immunology of infection. Ultimately, these studies will serve as a solid foundation on which future investigations of ARI epidemiology, treatment and prevention can be based.

Detailed Description

This is an observational, longitudinal study of ARI/ILI among otherwise healthy active duty military members, retirees, as well as their spouses and dependents. An additional cohort of HIV-infected adults will also be evaluated. We will collect data from clinical findings, medical chart review, and diagnostic, virologic, and immunologic assays to describe the epidemiology and immunology of ARI/ILI. Subject recruitment will take place in both inpatient and outpatient settings of military treatment facilities (MTF) in the continental US. Additionally, subject self-referral will be encouraged through institutional review board (IRB) approved advertisements. Both adults under 65 years of age and children will be eligible for participation. Subjects will be followed for a total of up to 4 visits over a 28±7-day period. After their final visit (Day 28±7 applicable window), participants may only re-enroll into the study after 3 months have passed.

Nasal swabs, blood specimens (if consented to), buccal cytobrush samples (if consented to), and rectal swabs (in select subgroups of consenting inpatients) will be collected in order to characterize the etiologic, epidemiologic, and immunologic characteristics of ARI in the study population. In the HIV- positive cohort, additional clinical data and blood will be collected for HIV-specific factors (e.g., CD4 counts, HIV RNA levels) and for additional immunologic studies at days 0 and 28 (± 7) of the study. This is a prospective longitudinal study which will use data from clinical findings, medical chart review, and diagnostic, virologic and immunologic laboratories to describe the epidemiology and immunology of ARI/ILI.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
2018
Inclusion Criteria
  • Between 18 and 55 years of age (inclusive), or a 17 year old military service member
  • Eligible for care in Department of Defense (DOD) facilities (DEERS eligible).
  • Have an acute influenza-like illness (ILI) or severe acute respiratory infection (SARI) for </= 7 days
Exclusion Criteria
  • None

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Number of subjects enrolled in the IDCRP ARI Consortium Natural History Study10 years

Clinical signs and symptoms,antibody titers (sera), serum cytokines and cell-mediated immunity (peripheral blood mononuclear cell activity), along with pathogen data (nasal swab/fecal swab), human leukocyte antigen (HLA) using a buccal swab, and fecal swabs to study the epidemiology, etiology , clinical characteristics and immunology of medically-attended ILI and SARI cases in this population.

Secondary Outcome Measures
NameTimeMethod
Develop and validate a patient-reported influenza outcome (Flu-PRO) instrument in patients with influenza-like illness6 months

Internal consistency reliability of the Flu-PRO Total and Domain scores on day 1

Impact of HIV-status on symptom severity, as measured by mean total composite score using Flu-Pro instrument, in subjects with influenza-like-illness1 year

Mean total composite symptom scores during the ILI episode were compared by HIV status using multivariate linear models, controlling for other factors such as influenza season, age, race, and military status. Measurement tool = Flu-Pro

Describe patterns of viral shedding by viral pathogen and pathogen subtype1 year

Serial nasal swabs collected from patients will be used to determine the duration of viral shedding

Trial Locations

Locations (5)

Walter Reed National Military Medical Center

🇺🇸

Bethesda, Maryland, United States

San Antonio Military Medical Center/Wilford Hall

🇺🇸

San Antonio, Texas, United States

Madigan Army Medical Center (MAMC)

🇺🇸

Tacoma, Washington, United States

Naval Medical Center, San Diego, CA

🇺🇸

San Diego, California, United States

Naval Medical Center, Portsmouth, VA

🇺🇸

Portsmouth, Virginia, United States

© Copyright 2025. All Rights Reserved by MedPath